These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1236 related articles for article (PubMed ID: 23534542)

  • 1. Treatment of HCV infection by targeting microRNA.
    Janssen HL; Reesink HW; Lawitz EJ; Zeuzem S; Rodriguez-Torres M; Patel K; van der Meer AJ; Patick AK; Chen A; Zhou Y; Persson R; King BD; Kauppinen S; Levin AA; Hodges MR
    N Engl J Med; 2013 May; 368(18):1685-94. PubMed ID: 23534542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
    van der Ree MH; van der Meer AJ; de Bruijne J; Maan R; van Vliet A; Welzel TM; Zeuzem S; Lawitz EJ; Rodriguez-Torres M; Kupcova V; Wiercinska-Drapalo A; Hodges MR; Janssen HL; Reesink HW
    Antiviral Res; 2014 Nov; 111():53-9. PubMed ID: 25218783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
    Ottosen S; Parsley TB; Yang L; Zeh K; van Doorn LJ; van der Veer E; Raney AK; Hodges MR; Patick AK
    Antimicrob Agents Chemother; 2015 Jan; 59(1):599-608. PubMed ID: 25385103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
    de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
    Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.
    van der Ree MH; van der Meer AJ; van Nuenen AC; de Bruijne J; Ottosen S; Janssen HL; Kootstra NA; Reesink HW
    Aliment Pharmacol Ther; 2016 Jan; 43(1):102-13. PubMed ID: 26503793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.
    Köberle V; Waidmann O; Kronenberger B; Andrei A; Susser S; Füller C; Perner D; Zeuzem S; Sarrazin C; Piiper A
    J Viral Hepat; 2013 Aug; 20(8):530-5. PubMed ID: 23808991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of systematic administration of Filgrastim to prevent neutropenia and infections in patient with hepatitis C.
    Sharvadze L; Karchava M; Bolokadze N; Gatserelia L; Tsertsvadze T
    Georgian Med News; 2009 Oct; (175):32-5. PubMed ID: 19893121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
    Soler M; McHutchison JG; Kwoh TJ; Dorr FA; Pawlotsky JM
    Antivir Ther; 2004 Dec; 9(6):953-68. PubMed ID: 15651754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
    Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
    Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
    van der Ree MH; de Vree JM; Stelma F; Willemse S; van der Valk M; Rietdijk S; Molenkamp R; Schinkel J; van Nuenen AC; Beuers U; Hadi S; Harbers M; van der Veer E; Liu K; Grundy J; Patick AK; Pavlicek A; Blem J; Huang M; Grint P; Neben S; Gibson NW; Kootstra NA; Reesink HW
    Lancet; 2017 Feb; 389(10070):709-717. PubMed ID: 28087069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
    McHutchison JG; Bacon BR; Gordon SC; Lawitz E; Shiffman M; Afdhal NH; Jacobson IM; Muir A; Al-Adhami M; Morris ML; Lekstrom-Himes JA; Efler SM; Davis HL
    Hepatology; 2007 Nov; 46(5):1341-9. PubMed ID: 17929306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion.
    Goldaracena N; Spetzler VN; Echeverri J; Kaths JM; Cherepanov V; Persson R; Hodges MR; Janssen HL; Selzner N; Grant DR; Feld JJ; Selzner M
    Am J Transplant; 2017 Apr; 17(4):970-978. PubMed ID: 27805315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.
    Saadoun D; Rosenzwajg M; Joly F; Six A; Carrat F; Thibault V; Sene D; Cacoub P; Klatzmann D
    N Engl J Med; 2011 Dec; 365(22):2067-77. PubMed ID: 22129253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV infection and miravirsen.
    Janssen HL; Kauppinen S; Hodges MR
    N Engl J Med; 2013 Aug; 369(9):878. PubMed ID: 23984739
    [No Abstract]   [Full Text] [Related]  

  • 18. HCV infection and miravirsen.
    Sanchez-Niño MD; Ortiz A
    N Engl J Med; 2013 Aug; 369(9):877-8. PubMed ID: 23984740
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.
    Lanford RE; Hildebrandt-Eriksen ES; Petri A; Persson R; Lindow M; Munk ME; Kauppinen S; Ørum H
    Science; 2010 Jan; 327(5962):198-201. PubMed ID: 19965718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir.
    Li YP; Van Pham L; Uzcategui N; Bukh J
    J Gen Virol; 2016 Jun; 97(6):1381-1394. PubMed ID: 26935756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.